Navigation Links
Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

3,644,530 4,896,607 5,661,077 Other revenues 198,592 1,505,737 945,286 2,761,069 Total Net Revenues 13,631,729 19,385,612 25,456,016 31,094,789 COST OF SALES 5,743,166 9,696,718 10,929,324 17,465,143 GROSS PROFIT 7,888,563 9,688,894 14,526,692 13,629,646 OPERATING EXPENSES: Selling expenses 1,801,235 5,875,549 3,503,034 6,997,886 Research and development -- 471,243 -- 1,181,468 General and administrative 769,103 542,043 1,516,309 1,168,460 Total Operating Expenses 2,570,338 6,888,835 5,019,343 9,347,814 INCOME FROM OPERATIONS 5,318,225 2,800,059 9,507,349 4,281,832 OTHER INCOME (EXPENSE): Debt issuance costs (99,516) (99,517) (199,033) (162,403) Interest income 44,793 2,027 46,112 2,588 Interest expense (470,551) (522,660) (918,648) (946,009) Total Other Income (Expense) (525,274) (620,150) (1,071,569) (1,105,824) INCOME BEFORE INCOME TAXES 4,792,951 2,179,909 8,435,780 3,176,008 INCOME TAXES 7,418 -- 82,145 -- NET INCOME $4,785,533 $2,179,909 $8,353,635 $3,176,008 COMPREHENSIVE INCOME: NET INCOME 4,785,533 2,179,909 8,353,635 3,176,008 OTHER COMPREHENSIVE INCOME: Unrealized foreign currency translation gain 2,896 1,587,538 65,007 3,041,741 COMPREHENSIVE INCOME $4,788,429 $3,767,447 $8,418,642 $6,217,749 NET INCOME PER COMMON SHARE: Basic
'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
2. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
3. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
4. NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
5. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
6. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
7. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... TEL AVIV, Israel , May 27, 2015 /PRNewswire/ ... the first quarter ended March 31, 2015. ... "In the quarter, we continued pre-clinical work to generate ... still in an early stage, we are encouraged by ... in this field as new antibodies which modulate immune ...
(Date:5/27/2015)...  Two years after its founding by a community ... Oakland -based Counter Culture Labs (CCL) ... to democratize science through a full-fledged community laboratory space ... Photo - http://photos.prnewswire.com/prnh/20150526/218366LOGO ... Based out of the new Omni Commons , ...
(Date:5/27/2015)... , May 27, 2015 ­ Caris ... the promise of precision medicine, today announced it has ... System, a center of excellence site in the Caris ... Levine Cancer Institute is one of the ... more than 11,000 new cancer patients annually. Derek ...
(Date:5/26/2015)... REDWOOD CITY , Kalifornien und HILDEN, ... QIAGEN Clinical Insight ... Interpretation von Genvarianten und die Erstellung dazugehöriger ... und ESHG     QIAGEN N.V. ... QIA) gab heute die Markteinführung von QIAGEN ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6
... JERUSALEM, June 3 The Gamida Cell-Teva ... three in Barcelona and two in Valencia, have joined the Excel ... alphabetical order:, - Hospital Clinic of Barcelona, Barcelona, ... - Hospital Clinico Universitario de Valencia, Valencia, ...
... Imaging(R), Inc., a wholly owned subsidiary of Pro Medicus ... Advanced Radiology Consultants to provide its enterprise-wide Visage(R) CS. ... Advanced Radiology Consultants is a multi-modality, multi-site imaging organization ... year. , , Dr. Gerard Muro, Chief of ...
... a wholly owned subsidiary of Microfluidics International Corporation ... entered into an exclusive distributorship agreement whereby POWREX ... fluid processors in the pharmaceutical, biotechnology and energy ... the second-largest individual country pharmaceutical market in the ...
Cached Biology Technology:Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 3Visage Imaging to Provide Visage(R) CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants 2Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries 2Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries 3Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries 4
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Through an innovative feat of plant biotechnology and vaccine ... University have successfully turned tobacco plants into vaccine production ... vaccine elicits a protective immune response in guinea pigs. ... the future development of a new vaccine for human ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
... Just as baby mammals depend on their mothers' milk, ... themselves by stripping off and eating the fat-rich outer ... team of researchers that includes University of Michigan biologist ... issue (April 13) of the journal Nature. , Hatchlings ...
Cached Biology News:Plant-derived vaccines safeguard against deadly plague 2Plant-derived vaccines safeguard against deadly plague 3Do plants have the potential to vaccinate against HIV? 2African amphibians make extreme parental sacrifice: The skin off their backs 2African amphibians make extreme parental sacrifice: The skin off their backs 3
... The Lambda 10-2 is a microprocessor ... impressive speed coupled with exceptionally smooth ... for research applications involving fluorescence microscopy, ... any application requiring rapid and accurate ...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... a-Amylase is an enzyme that ... mixture of maltose, maltotriose, and dextrins. ... of the human body is of,clinical ... states including,pancreatitis and diabetes; plant and ...
... has recently launched a custom synthesis ... (siRNA). Thermos siRNA molecules are: ... 2 DNA bases overhang at the ... Delivered fully deprotected and ready-to-use. ...
Biology Products: